Want to see AU:IIQ full AI Analyst Report?
IIQ Stock Chart & Stats
AU$0.40
AU$0.02(3.09%)
At close: 4:00 PM EST
AU$0.40
AU$0.02(3.09%)
Day’s Range― - ―
52-Week RangeAU$0.16 - AU$0.57
Previous CloseN/A
Volume76.26K
Average Volume (3M)118.34K
Market Cap
AU$21.82M
Enterprise ValueAU$67.66M
Total Cash (Recent Filing)AU$9.35M
Total Debt (Recent Filing)AU$289.39K
Price to Earnings (P/E)―
Beta0.30
Next Earnings
Feb 19, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.06
Shares Outstanding140,775,450
10 Day Avg. Volume129,162
30 Day Avg. Volume118,344
Financial Highlights & Ratios
PEG Ratio1.11
Price to Book (P/B)3.81
Price to Sales (P/S)166.47
P/FCF Ratio-10.98
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.07
Revenue Forecast (FY)AU$1.90M
Bulls Say, Bears Say
Bulls Say
Low Financial LeverageVery low leverage limits interest and refinancing pressure while preserving financial flexibility. This gives INOVIQ more room to fund diagnostic development, pursue collaborations, or manage periods of weak commercialization without the added constraints of a heavily debt-funded balance sheet.
Platform-based Commercial ModelThe business model combines diagnostic offerings, research-use products and collaboration income around a common biomarker technology base. If commercial execution improves, multiple routes to monetisation could support broader customer reach and reduce reliance on one product or channel.
Losses Have Narrowed From FY2022Although profitability remains negative, the reduction in losses from the extreme FY2022 level indicates some improvement in financial performance over the longer period. Further progress could reduce funding needs and strengthen the path toward sustainable economics as revenue develops.
Bears Say
Sharp Revenue ContractionA sharp revenue decline leaves the company operating at a very small scale and makes commercial traction less dependable. Lower sales reduce the ability to absorb fixed research and operating costs, increasing the difficulty of reaching sustainable margins over the coming quarters.
Persistent Unprofitable OperationsLarge recurring losses show that the current revenue base does not yet support the operating cost structure. Continued unprofitability can consume capital, limit reinvestment choices and make future progress dependent on successfully scaling products, services or partnerships.
Ongoing Cash BurnPersistent negative operating cash flow means INOVIQ is funding operations and investment from its balance sheet rather than internally generated cash. The deterioration in FY2026 increases the importance of improving revenue conversion and controlling cash usage to preserve financial flexibility.
Inoviq Ltd News
IIQ FAQ
What was Inoviq Ltd’s price range in the past 12 months?
Inoviq Ltd lowest share price was AU$0.15 and its highest was AU$0.56 in the past 12 months.
What is Inoviq Ltd’s market cap?
Inoviq Ltd’s market cap is AU$21.82M.
When is Inoviq Ltd’s upcoming earnings report date?
Inoviq Ltd’s upcoming earnings report date is Feb 19, 2027 which is in 129 days.
How were Inoviq Ltd’s earnings last quarter?
Inoviq Ltd released its earnings results on Sep 16, 2026. The company reported -AU$0.025 earnings per share for the quarter.
Is Inoviq Ltd overvalued?
According to Wall Street analysts Inoviq Ltd’s price is currently Overvalued.
Does Inoviq Ltd pay dividends?
Inoviq Ltd does not currently pay dividends.
What is Inoviq Ltd’s EPS estimate?
Inoviq Ltd’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Inoviq Ltd have?
Inoviq Ltd has 140,775,450 shares outstanding.
What happened to Inoviq Ltd’s price movement after its last earnings report?
Inoviq Ltd reported an EPS of -AU$0.025 in its last earnings report. Following the earnings report the stock price went up 2.941%.
Which hedge fund is a major shareholder of Inoviq Ltd?
Currently, no hedge funds are holding shares in AU:IIQ
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Inoviq Ltd Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-62.65%
12-Months-Change
Fundamentals
Return on Equity
-36.48%
Trailing 12-Months
Asset Growth
10.81%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Inoviq Ltd
INOVIQ Ltd specializes in the research, development, and commercialization of diagnostic and exosome-based products, aiming to improve the detection and treatment of cancer and other conditions across Australia and the United States. Its current portfolio includes the hTERT test, an immunocytochemistry assay that serves as a supplementary tool for urine cytology in bladder cancer screening, alongside EXO-NET, designed for the capture and isolation of exosomes from liquid biopsy specimens. The company also boasts a robust diagnostic pipeline, featuring blood tests currently under development for various cancers, including ovarian and breast cancer. Originally incorporated in 1983 and formerly known as BARD1 Life Sciences Limited until its rebranding to INOVIQ Ltd in December 2021, the company maintains its headquarters in Notting Hill, Australia.
Technical Analysis
―
BCAL Diagnostics Limited
―
Rhythm Biosciences Ltd.
―
Genetic Signatures Ltd.
―
Imagion Biosystems Ltd.
―